Summit Therapeutics SMMT EBITDA
Discontinued — last reported Q4 '24
EBITDA at other companies
Other financials
Where this comes from
Calculated from Summit Therapeutics’s reported figures.
The official record: Summit Therapeutics’s 10-K, filed February 23, 2026, on SEC EDGAR. View the filing →
Ask your AI about Summit Therapeutics's ebitda.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Summit Therapeutics's EBITDA?
- Summit Therapeutics (SMMT) reported EBITDA of -$65.59M in Q4 2024.
- How has Summit Therapeutics's EBITDA changed year-over-year?
- Summit Therapeutics's EBITDA decreased by 81.3% year-over-year, from -$36.18M to -$65.59M.
- What is the long-term trend for Summit Therapeutics's EBITDA?
- Over 3 years (2021 to 2024), Summit Therapeutics's EBITDA has grown at a 38.6% compound annual growth rate (CAGR), from -$84.84M to -$225.91M.
- What does EBITDA mean?
- Operating cash profit before interest, taxes, and non-cash charges.
- How do you interpret EBITDA?
- Higher is better and widely used to value capital-intensive businesses, but it ignores the real cost of capex — pair it with free cash flow. (Defined as EBIT + D&A so EBITDA = EBIT + D&A holds exactly.)
- How does EBITDA compare across companies?
- Standard cross-company operating-profit proxy for non-financials; not meaningful for banks and insurers.